Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
“137 [100 37 19]).”
Self-citationO’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Self-citationBlumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30295-2 · Cited by 1,363
Depression and cardiovascular disease: a clinical review
Hare, D. L., Toukhsati, S. R., Johansson, P., & Jaarsma, T. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht462 · Cited by 1,362
“In non-cardiac patients, after initially trying the SSRI citalopram, switching to another anti-depressant can result in additional benefits.(88) Because it more resembles a tricyclic antidepressant when”
BackgroundGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
“In a landmark study of treatment-resistant depressed adults, after unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant (Rush et al., 2006 [rct], Trivedi et al., 2006 [rct]).”
BackgroundMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citationFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Self-citationAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Self-citationBrent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., Vitiello, B., Ritz, L., Iyengar, S., Abebe, K., et al. (2008) · JAMA · doi:10.1001/jama.299.8.901 · Cited by 700
Self-citationMcClintock, S. M., Reti, I. M., Carpenter, L. L., McDonald, W. M., Dubin, M., Taylor, S. F., Cook, I. A., O’Reardon, J., Husain, M. M., Wall, C., et al. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16cs10905 · Cited by 693
“Examples include (1) treatment of primary psychiatric conditions other than MDD without psychotic features,76,77 (2) administering more than 3,000 pulses per session,78 (3) stimulation of the right prefrontal cortex,10,72 and (4) use of devices with FDA approval for delivering peripheral nerve stimulation (eg, Neotonu…”
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Self-citationThe Antidepressive Effects of Exercise: A Meta-Analysis of Randomized Trials
Rethorst, C. D., Wipfli, B. M., & Landers, D. M. (2009) · Sports Medicine · doi:10.2165/00007256-200939060-00004 · Cited by 541
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Brunoni, A. R., Chaimani, A., Moffa, A. H., Razza, L. B., Gattaz, W. F., Daskalakis, Z. J., & Carvalho, A. F. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3644 · Cited by 520
“The treatment options available are suboptimal, with most patients being refractory.(2) Therefore, there is an urgent need to develop and optimize novel treatments for depression, such as repetitive transcranial magnetic stimulation (rTMS).”
BackgroundConnolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Self-citation(2007) · PubMed · Cited by 453
Kroenke, K., Bair, M. J., Damush, T. M., Wu, J., Hoke, S., Sutherland, J., & Tu, W. (2009) · JAMA · doi:10.1001/jama.2009.723 · Cited by 447
Goodwin, G., & Consensus Group of the British Association for Psychopharmacology (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 444
Stuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 430
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“For example, in the STAR*D effectiveness trial, there were no differences in response or remission rates when non-remitters to citalopram were switched to another SSRI (sertraline) or to non-SSRI agents (bupropion-SR or venlafaxine-XR) (Rush et al., 2006).”
BackgroundBrunoni, A. R., Moffa, A. H., Fregni, F., Palm, U., Padberg, F., Blumberger, D. M., Daskalakis, Z. J., Bennabi, D., Haffen, E., Alonzo, A., et al. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.164715 · Cited by 414
George, M. S., & Aston-Jones, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.87 · Cited by 401
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review
Sinyor, M., Schaffer, A., & Levitt, A. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500303 · Cited by 396
“HDRS remission rates were 28% using intent-to-treat analysis in Level 1 and ranged from 18% (sertraline switch) to 30% (buspirone augmentation) in Level 2 (Figure 1).(5,20,28,29) HDRS remission rates ranged from 12% (mirtazapine switch) to 25% (T3 augmentation) and 7% (tranylcypromine switch) to 14% (venlafaxine XR +…”
MethodGlutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111645 · Cited by 372
Self-citationPersonalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365
“For example, among patients who do not benefi t from initial treatment with one antidepressant, up to one-half experience signifi cant improvement after switching to an alternative medication (8), adding a second medication (9), or adding psychotherapy (10).”
BackgroundMcCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Self-citationGartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
“The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial (63) provides the best evidence for assessing alternative medications among patients in whom initial therapy has failed.”
BackgroundBupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Self-citationEfficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332
Self-citationBlier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316
Collaborative care for bipolar disorder, Part II: impact on clinical outcome, function, and costs.
Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., & Sajatovic, M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.937 · Cited by 312
National trends in the treatment for depression from 1998 to 2007
Marcus, S. C., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.151 · Cited by 312
Guo, T., Xiang, Y.-T., Xiao, L., Hu, C.-Q., Chiu, H. F. K., Ungvari, G. S., Correll, C. U., Lai, K. Y. C., Feng, L., Geng, Y., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14050652 · Cited by 308
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Self-citationThe burden of severe depression: A review of diagnostic challenges and treatment alternatives
Nemeroff, C. B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.008 · Cited by 295
“, 2003) is beginning to provide data (Rush et al., 2006; Trivedi et al., 2006) on strategies for addressing failed antidepressant intervention, although this trial includes only outpatients with non-psychotic depression.”
BackgroundPapakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Self-citationLenze, E. J., Mulsant, B. H., Blumberger, D. M., Karp, J. F., Newcomer, J. W., Anderson, S. J., Dew, M. A., Butters, M. A., Stack, J. A., Begley, A. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00308-6 · Cited by 283
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279
“Low-quality evidence from 1 trial (40) showed no difference in remission (bupropion vs.”
BackgroundInfluentialDandekar, M. P., Fenoy, A. J., Carvalho, A. F., Soares, J. C., & Quevedo, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2018.2 · Cited by 266
Kantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
“Moreover, only around 30% of treated patients with MDD achieve satisfactory remission, despite receiving medications with different mechanisms of action and subsequently different treatment strategies (Rush et al., 2006 ; Trivedi et al., 2006).”
BackgroundAccelerated TMS for Depression: A systematic review and meta-analysis
Sonmez, A. I., Camsari, D. D., Nandakumar, A. L., Voort, J. L. V., Kung, S., Lewis, C. P., & Croarkin, P. E. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.041 · Cited by 255
“Prior antidepressant resistance also decreases the likelihood of responding to subsequent interventions (Rush et al., 2006).”
BackgroundConsensus statement: The evaluation and treatment of people with epilepsy and affective disorders
Barry, J. J., Ettinger, A. B., Friel, P., Gilliam, F. G., Harden, C. L., Hermann, B., Kanner, A. M., Caplan, R., Plioplys, S., Salpekar, J., et al. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.04.005 · Cited by 249
“buspirone resulted in remission in approximately one-third of patients [290].”
BackgroundThe STAR*D study: treating depression in the real world.
Gaynes, B. N., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Spencer, D., & Fava, M. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.1.57 · Cited by 248
“The remission rate was approximately one-fourth with all three drugs 31 Though the types of side effects related to specific medications may have varied, the overall side-effect burden and the rate of serious adverse events did not differ significantly.”
Self-citationIs the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Menke, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00101 · Cited by 240
“Although a range of effective antidepressants are available, more than 50% of patients do not respond to the first antidepressant treatment they are prescribed (4) and around 30% fail to respond even after several treatment approaches (5).”
BackgroundThe role of serotonin receptor subtypes in treating depression: a review of animal studies
Carr, G. V., & Lucki, I. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2097-z · Cited by 239
“This feature of differential vulnerability is present in human depression, as not all people respond equally when presented with the same stressor (Kendler et al. 2004) and a high percentage of patients do not respond to antidepressant treatment (Rush et al. 2006).”
BackgroundGartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
“Although limited evidence indicates that the efficacy of second-generation antidepressants is similar among patients for whom treatment with a first-line agent failed, a substantial proportion of these patients do not achieve response or remission with second-line treatment (56).”
BackgroundInfluentialJanicak, P. G., O'Reardon, J. P., Sampson, S. M., Hussain, M. M., Lisanby, S. H., Rado, J. T., Heart, K. L., & Demitrack, M. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0208 · Cited by 235
Management of Depression in Adults: A Review
Simon, G. E., Moise, N., & Mohr, D. C. (2024) · JAMA · doi:10.1001/jama.2024.5756 · Cited by 234
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
“Further studies are needed to evaluate its long-term antidepressant efficacy in patients with TRD. Keywords: Antidepressant effect, ketamine, NMDA receptors, pharmacological properties, treatment-resistant depression.”
Trivedi, M. H., Greer, T. L., Church, T. S., Carmody, T. J., Grannemann, B. D., Galper, D. I., Dunn, A. L., Earnest, C. P., Sunderajan, P., Henley, S. S., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06743 · Cited by 232
Self-citationTrial of SAGE-217 in Patients with Major Depressive Disorder
Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815981 · Cited by 232
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232
“While therapeutic strategies such as switching antidepressants and using adjuvant drug treatments can improve response, almost 40% of patients remain symptomatic and fail to achieve full remission (5, 6).”
BackgroundSelf-citationRuhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
Unützer, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp073754 · Cited by 222
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Rethorst, C. D., Toups, M. S., Greer, T. L., Nakonezny, P. A., Carmody, T. J., Grannemann, B. D., Huebinger, R. M., Barber, R. C., & Trivedi, M. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.125 · Cited by 211
Self-citationPilowsky, D. J., Wickramaratne, P., Talati, A., Tang, M., Hughes, C. W., Garber, J., Malloy, E., King, C., Cerda, G., Sood, A. B., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07081286 · Cited by 210
Self-citationHall-Flavin, D. K., Winner, J. G., Allen, J. D., Carhart, J. M., Proctor, B., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Geske, J., & Mrazek, D. A. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283649b9a · Cited by 209
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
Self-citationBupropion: a systematic review and meta-analysis of effectiveness as an antidepressant
Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316629071 · Cited by 194
“…al., 2006), five with sertraline (Coleman et al., 1999; Croft et al., 1999; Kavoussi, Segraves, Hughes, Ascher, & Johnston, 1997; Rush et al., 2001; Rush et al., 2006), two with fluoxetine (Coleman et al., 2001; Feighner et al., 1991) and two with paroxetine (Grunebaum et al., 2012; Kennedy et…”
BackgroundMethodDepression and coronary artery disease: the association, mechanisms, and therapeutic implications.
Khawaja, I. S., Westermeyer, J. J., Gajwani, P., & Feinstein, R. E. (2009) · PubMed Central · Cited by 270
Mantani, A., Kato, T., Furukawa, T. A., Horikoshi, M., Imai, H., Hiroe, T., Chino, B., Funayama, T., Yonemoto, N., Zhou, Q., et al. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.8602 · Cited by 192
“Secondary outcomes included the FIBSER, which assesses the frequency, intensity, and burden of side effects, each on a 7-point scale, with a total score between 3 and 27, [49] and the BDI-II [43], a self-report measure of depression severity that asks about 21 symptoms of depression, each on a scale between 0 and 3, w…”
Garlow, S. J., Dunlop, B. W., Ninan, P. T., & Nemeroff, C. B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.009 · Cited by 192
“…second antidepressants, atypical antipsychotics, pindolol, electroconvulsive therapy (ECT) and psychotherapies (Aronson et al., 1996; Bauer et al., 2003; Keitner et al., 2009; Maes et al., 1999; Nierenberg et al., 2006; Papkostas and Shelton, 2008; Rush et al., 2006b; Trivedi et al., 2006a).”
Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190
“Another limitation of current monoamine-based antidepressants was high-lighted in the large well-known trial; sequenced treatment alternative to relieve depression (STAR n D Trial) (Rush et al., 2006a, 2006b; Trivedi et al., 2006; Nierenberg et al., (2006); Rush, 2006c; Fava et al., 2006).”
BackgroundExtended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?
Clayton, A. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.457 · Cited by 186
“(2007) 8(4) among the three treatments tested [53].”
BackgroundBauer, M., Monz, B. U., Montejo, A. L., Quail, D., Dantchev, N., Demyttenaere, K., Garcia-Cebrian, A., Grassi, L., Perahia, D. G. S., Reed, C., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2007.11.001 · Cited by 186
“[26] investigated switching antidepressants due to intolerability or not achieving remission with initial treatment with citalopram.”
BackgroundUsing a pharmacogenomic algorithm to guide the treatment of depression
Hall-Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Biernacka, J. M., & Mrazek, D. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.99 · Cited by 185
“These categories were (1) ‘use as directed,’ (2) ‘use with caution’ and (3) ‘use with caution and more frequent monitoring.”
BackgroundA vision of the next generation of behavioral therapies research in the addictions*
Carroll, K. M., & Rounsaville, B. J. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01798.x · Cited by 177
Rush, A. J., Wisniewski, S. R., Warden, D., Luther, J. F., Davis, L. L., Fava, M., Nierenberg, A. A., & Trivedi, M. H. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.8.870 · Cited by 176
“Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.”
BackgroundMethodInfluentialSelf-citationThe role of exercise in the treatment of depression: biological underpinnings and clinical outcomes
Ross, R. E., VanDerwerker, C. J., Saladin, M. E., & Gregory, C. M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01819-w · Cited by 176
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14020181 · Cited by 175
“Not only does treatment outcome vary substantially among depressed patients who are treated in a similar fashion (5), but there is little evidence that one treatment is superior to another, whether comparing among antidepressant medications (6), among psychotherapies (7), or between the two (8).”
BackgroundSelf-citationSerotonin and Norepinephrine Reuptake Inhibitors
Shelton, R. C. (2018) · Handbook of Experimental Pharmacology · doi:10.1007/164_2018_164 · Cited by 171
Moffa, A. H., Martin, D., Alonzo, A., Bennabi, D., Blumberger, D. M., Benseñor, I. M., Daskalakis, Z., Fregni, F., Haffen, E., Lisanby, S. H., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109836 · Cited by 171
“Pharmacological treatments are limited as one-third of patients are treatment-resistant (Rush et al., 2006).”
HUGHES, C. W., EMSLIE, G. J., CRISMON, M. L., POSNER, K., BIRMAHER, B., RYAN, N., JENSEN, P., CURRY, J., VITIELLO, B., LOPEZ, M., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31804a859b · Cited by 168
“adults with MDD in the public sector (Rush et al., 2006; Trivedi et al., 2004).”
BackgroundMethodInfluentialSelf-citationSchramm, E., van Calker, D., Dykierek, P., Lieb, K., Kech, S., Zobel, I., Leonhart, R., & Berger, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.768 · Cited by 169
Qaseem, A., Snow, V., Denberg, T. D., Forciea, M. A., & Owens, D. K. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00007 · Cited by 165
“One large good-quality study, STAR*D (Sequenced Treatment Alternatives to Relieve Depression) (33), provided the best evidence for assessing alternative medications (sustained-release bupropion, sertraline, and extended-release venlafaxine) in patients whose initial therapy failed; it showed that 1 in 4 patients becam…”
BackgroundSystematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders
Stuart, M. J., Singhal, G., & Baune, B. T. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00357 · Cited by 163
“Despite the global significance of these disorders, many patients remain resistant to current psychosocial and pharmacological interventions (Murdoch and Finn, 2000; Ono et al., 2003; Rush et al., 2006a,b; Trivedi et al., 2006).”
BackgroundTreatment-Resistant Depression and Mortality After Acute Coronary Syndrome
Carney, R. M., & Freedland, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081239 · Cited by 163
NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice
Li, D., Wang, Y., Jin, X., Hu, D., Xia, C., Xu, H., & Hu, J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01787-4 · Cited by 163
“At present, the commonly used antidepressants in clinical use increase the concentration of monoamines in the synapse, but these drugs have a slow effect, and for patients with serious symptoms, they typically have no effect [30].”
MethodFood for Mood: Relevance of Nutritional Omega-3 Fatty Acids for Depression and Anxiety
Larrieu, T., & Layé, S. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01047 · Cited by 162
Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.015 · Cited by 161
Depression: the benefits of early and appropriate treatment.
Halfin, A. (2007) · PubMed · Cited by 220
Mohamed, S., Johnson, G. R., Chen, P., Hicks, P. B., Davis, L. L., Yoon, J., Gleason, T. C., Vertrees, J. E., Weingart, K., Tal, I., et al. (2017) · JAMA · doi:10.1001/jama.2017.8036 · Cited by 159
Self-citation
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.